The Wegovy Pill and the Wegovy Shot Are One Label, One Blood Level, and Ten Times the Milligrams

They are not two drugs

The first thing worth knowing is administrative, and it settles more of this question than any comparison chart: the tablet and the injection are approved under one FDA label. Not two products that happen to share a name — one prescribing document, covering "WEGOVY (semaglutide) injection, solution" and "WEGOVY (semaglutide) tablet" together, with the same boxed warning, the same contraindications, and the same list of who should not take it.

That is unusual enough to be informative. The FDA did not treat the pill as a new medicine. It treated it as a second way into the same one.

The number that answers the question

Most comparisons of these two forms talk about convenience. The label talks about concentration, and its own pharmacokinetics section contains the pair of figures that actually decides the matter.

The label states the conclusion in its own words: semaglutide concentrations following once-daily oral Wegovy 25 mg are predicted to be comparable to Wegovy 2.4 mg once weekly.

So the honest answer to "which one is stronger" is that, at their maintenance doses, neither is. They put a near-identical amount of the same molecule into your blood and hold it there.

Then why is the pill dose ten times bigger?

Because almost none of it survives the trip.

The label gives absolute bioavailability for both routes, and the gap is the whole story:

Injected, nearly nine-tenths of the dose reaches circulation. Swallowed, roughly one to two hundredths does. The tablet is co-formulated with an absorption enhancer called SNAC, and absorption happens predominantly in the stomach rather than the intestine — but even with that, 25 mg by mouth is what it takes to land where 2.4 mg by needle lands.

The 25 mg is not a bigger dose. It is the same dose after your gut has destroyed most of it.

Which is why the morning rules are not housekeeping

Every set of instructions for the tablet reads like fussy small print. Read against a 1–2% margin, it stops being fussy.

The label's administration instructions are specific and they are all in service of that margin:

• Take it on an empty stomach, in the morning.
• With water only — no more than 4 ounces, and no other liquids.
• Swallow whole. Do not split, crush, chew, or dissolve it in anything.
• Wait at least 30 minutes before eating, before drinking anything else, and before taking any other oral medication.
• One tablet a day, never two.

If you take an injection, food is irrelevant — the label says explicitly that Wegovy injection can be taken with or without food. If you take the tablet, the thirty minutes before breakfast is the mechanism. A reader who shortens it because a child needs something is not taking a slightly weaker dose that morning. She is introducing the exact variable the trials controlled for.

For a mother, that is the difference that matters more than any efficacy figure, and it is worth being honest about which one your actual mornings can absorb. A weekly injection asks for ninety seconds once a week. A daily tablet asks for a protected half-hour, three hundred and sixty-five times a year, starting before anyone else in the house is fed.

What each one did in its own trial

Neither of these is a comparison. They are two separate placebo-controlled trials, run years apart, in different populations.

The tablet — OASIS 4. A 71-week, double-blind, randomized, placebo-controlled trial at 22 sites across four countries. 205 participants on oral semaglutide 25 mg, 102 on placebo, none with diabetes. At week 64, mean body weight change was −13.6% versus −2.2% on placebo — an estimated difference of −11.4 percentage points (95% CI, −13.9 to −9.0)¹.

The injection — STEP 1. A 68-week double-blind trial in 1,961 adults without diabetes. Mean body weight change was −14.9% versus −2.4% on placebo, an estimated treatment difference of −12.4 percentage points (95% CI, −13.4 to −11.5)².

Those look close, and the temptation is to subtract one from the other. Resist it: different trials, different sizes, different years, different placebo arms. A difference read across two studies is not a measured difference.

The comparison in circulation, and who paid for it

There is a published comparison, and it is worth knowing exactly what it is.

A 2026 analysis in Diabetes, Obesity and Metabolism ran a naïve Bucher indirect treatment comparison, stitching OASIS 4 to STEP 1 through their placebo arms. It found the two forms comparable across every outcome assessed. On percentage weight change the injection held a small numerical advantage — an estimated treatment difference of 1.01 percentage points (95% CI, −1.61 to 3.63) — with the authors noting this sits well below the FDA's 5% threshold for clinical relevance. Safety profiles were broadly comparable³.

The confidence interval crosses zero, which is the part that matters: the analysis cannot distinguish the two.

The paper's own conflict-of-interest statement records that three authors were employed by Novo Nordisk, which makes both forms; one served as a health economic adviser to Novo Nordisk; two were employees of a firm, Petauri Evidence, that Novo Nordisk contracted to undertake the study; and one sat on a Novo Nordisk advisory board³.

That does not make the finding wrong. Manufacturer-sponsored indirect comparisons are routine, and a result showing your new oral product is merely equivalent to your existing injection is not a flattering one to manufacture. It does mean that no trial has ever randomized a single person between the pill and the shot, and until one does, "they work about the same" is an inference, not a measurement.

The pill is not the gentle option

This is the assumption worth dismantling, because it is the reason many women ask about the tablet in the first place.

The label evaluated the 25 mg tablet in a trial of 204 adults with obesity or overweight, 76% of them women, for up to 64 weeks. Its verdict on side effects is one sentence, and it is unambiguous: the types and frequency of common adverse reactions were similar to those listed in Table 3 — Table 3 being the injection's own adverse-reaction table.

Which is this one:

In the tablet trial itself, 6.9% of patients discontinued permanently because of adverse reactions, against 5.9% on placebo, with gastrointestinal reactions the most common reason (3.4% versus 2%).

Swallowing it instead of injecting it does not route the drug around your stomach. It routes it through your stomach — which is where the tablet is absorbed in the first place. In OASIS 4, gastrointestinal adverse events occurred in 74.0% of the oral semaglutide group against 42.2% on placebo¹.

If nausea is the thing you are trying to avoid, the form is not the lever. What helps with GLP-1 side effects while you are running a household is the more useful page for that.

So how do you actually choose?

On the evidence available, not on effectiveness — that is the one axis where the label says they land in the same place.

The injection asks less of your day. Once a week, with or without food, and then you stop thinking about it. If your mornings are not yours, this is the form that survives contact with them.

The tablet asks less of your nerve. For someone who will genuinely not inject — a real reason, not a soft one — a daily tablet reaching the same blood level costs nothing in results. It costs mornings.

Neither is a milder drug. The same boxed warning, the same contraindications, the same adverse-reaction profile, the same molecule at the same concentration.

One practical note: the tablet starts at 1.5 mg daily for 30 days, then steps every 30 days to the 25 mg maintenance dose; the injection starts at 0.25 mg weekly and steps every 4 weeks to 2.4 mg. Neither is quick, and if you do not tolerate a step, the label's instruction for both is the same — consider delaying the escalation rather than pushing through it.

What is not yet known

Two gaps are worth carrying, because the marketing for the tablet does not mention either.

The first is that the tablet's weight-reduction indication carries an accelerated-approval caveat on its own label: continued approval for that indication may be contingent on verification and description of clinical benefit in a confirmatory trial.

The second is the one this whole page circles. There is no head-to-head. Everything anyone tells you about how the pill compares to the shot — including everything on this page — is two trials read alongside each other, plus one indirect comparison funded by the company that sells both.

That is enough to say they are probably close. It is not enough for anyone to promise you a difference in either direction.